In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies
Friday, 24 June, 2005
The sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed. A 90-day convertible note has been issued by Advance to Pharmanet, satisfying the $400,000 settlement payment.
David Kenley, VP corporate development and one of the founders of Metabolic Pharmaceuticals (ASX:MBP), has resigned from the company to become CEO of Xceed Biotechnology (ASX:XBL). Kenley will leave Metabolic on 1 July and join Xceed in mid July.
Henry Bosch has been appointed as a non-executive director of Genetic Technologies (ASX:GTG).
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
